Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Historical BCRX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bearish Signal Line Cross | Bearish | 0.00% | |
Earnings Movers | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Stochastic Reached Overbought | Strength | -8.00% | |
Earnings Movers | Other | -8.00% | |
Wide Bands | Range Expansion | -8.00% | |
Overbought Stochastic | Strength | -8.00% | |
Shooting Star Candlestick | Bearish | -6.98% | |
NR7 | Range Contraction | -6.98% | |
Wide Bands | Range Expansion | -6.98% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Down 1 ATR | about 7 hours ago | |
60 Minute Opening Range Breakdown | about 7 hours ago | |
10 DMA Support | about 10 hours ago | |
Down 5% | about 10 hours ago | |
Fell Below 10 DMA | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/03/2021
BioCryst Pharmaceuticals, Inc. Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Diseases Chemical Compounds Influenza Coronavirus Enzymes Viruses Angioedema Drug Design Hereditary Angioedema Medicinal Chemistry Gout Kallikrein Seasonal Influenza Acetamides Crystallography Protease Inhibitor
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.9 |
52 Week Low | 1.58 |
Average Volume | 6,967,296 |
200-Day Moving Average | 5.74 |
50-Day Moving Average | 9.31 |
20-Day Moving Average | 10.65 |
10-Day Moving Average | 11.34 |
Average True Range | 0.92 |
ADX | 40.75 |
+DI | 29.30 |
-DI | 18.81 |
Chandelier Exit (Long, 3 ATRs ) | 10.15 |
Chandelier Exit (Short, 3 ATRs ) | 11.61 |
Upper Bollinger Band | 12.34 |
Lower Bollinger Band | 8.97 |
Percent B (%b) | 0.58 |
BandWidth | 31.67 |
MACD Line | 0.64 |
MACD Signal Line | 0.66 |
MACD Histogram | -0.02 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.75 | ||||
Resistance 3 (R3) | 12.91 | 12.46 | 12.45 | ||
Resistance 2 (R2) | 12.46 | 11.99 | 12.38 | 12.35 | |
Resistance 1 (R1) | 11.69 | 11.71 | 11.47 | 11.53 | 12.24 |
Pivot Point | 11.24 | 11.24 | 11.13 | 11.16 | 11.24 |
Support 1 (S1) | 10.47 | 10.77 | 10.24 | 10.31 | 9.60 |
Support 2 (S2) | 10.02 | 10.48 | 9.94 | 9.49 | |
Support 3 (S3) | 9.25 | 10.02 | 9.39 | ||
Support 4 (S4) | 9.09 |